Valuation: Madrigal Pharmaceuticals, Inc.

Market Cap 12.42B 10.84B 10.11B 9.3B 17.44B 1,188B 17.88B 120B 46.83B 589B 46.64B 45.63B 2,030B P/E 2026 *
-76.6x
P/E 2027 * 64.3x
Enterprise Value 11.91B 10.39B 9.69B 8.92B 16.72B 1,139B 17.14B 115B 44.89B 564B 44.7B 43.73B 1,945B EV / Sales 2026 *
7.92x
EV / Sales 2027 * 5.22x
Free-Float
94.11%
Yield 2026 *
-
Yield 2027 * -
1 day+1.50%
1 week+0.02%
Current month+1.85%
1 month+6.68%
3 months+5.84%
6 months+10.14%
Current year-6.09%
1 week 526.6
Extreme 526.605
566.18
1 month 507.6
Extreme 507.6
569.44
Current year 416.21
Extreme 416.21
598.79
1 year 286.44
Extreme 286.44
615
3 years 119.76
Extreme 119.7604
615
5 years 52.33
Extreme 52.33
615
10 years 6.6
Extreme 6.6
615
Manager TitleAgeSince
Chief Executive Officer 59 08/09/2023
Director of Finance/CFO 62 11/03/2024
Chief Tech/Sci/R&D Officer 58 21/04/2025
Director TitleAgeSince
Director/Board Member 74 01/07/2016
Director/Board Member 68 11/08/2016
Director/Board Member 64 27/06/2019
Date Insider Type Main position Quantity % Market Cap.
20/7/26 Sell

Chief Executive Officer

-2,500 0.0108%
17/6/26
Baker Bros. Advisors LP
FreeCompany 4,880 0.0212%
17/6/26 Free

Director

1,220 0.0053%
Change 5-day change 1-year change 3-year change Capi.($)
+1.50%+0.02%+85.91%+166.11% 12.42B
+0.47%+2.03%+51.54%+70.84% 55.01B
+2.83%+0.04%+38.07%+82.59% 54.24B
+0.54%+0.67%-17.59%-13.47% 23.38B
-0.97%-5.06%+1.35%+383.00% 22.57B
+2.07%+1.44%+23.06%-9.05% 20.19B
-2.15%+0.78%+24.67%-31.03% 17.86B
-2.14%-2.72%+30.26%+536.72% 15.5B
-3.14%-8.09%+160.68%+292.18% 14.2B
-2.09%-1.41%+24.65%+178.74% 14.2B
Average -0.31%-0.21%+42.26%+165.66% 24.96B
Weighted average by Cap. +0.34%-0.05%+38.44%+132.38%

Financials

2026 *2027 *
Net sales 1.5B 1.31B 1.22B 1.13B 2.11B 144B 2.16B 14.5B 5.67B 71.25B 5.64B 5.52B 246B 2.17B 1.9B 1.77B 1.63B 3.05B 208B 3.13B 20.97B 8.2B 103B 8.16B 7.99B 355B
Net income -197M -172M -160M -147M -276M -18.83B -283M -1.9B -742M -9.33B -739M -723M -32.16B 269M 235M 219M 202M 378M 25.75B 388M 2.6B 1.02B 12.76B 1.01B 989M 43.99B
Net Debt -515M -449M -419M -386M -723M -49.27B -741M -4.97B -1.94B -24.42B -1.93B -1.89B -84.16B -1.08B -939M -876M -806M -1.51B -103B -1.55B -10.38B -4.06B -51B -4.04B -3.95B -176B
Logo Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. The Company’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-b agonist designed to target key underlying causes of MASH. Rezdiffra is the medication approved by the United States Food and Drug Administration (FDA) for the treatment of MASH with moderate to advanced fibrosis (consistent with stages F2 to F3). Rezdiffra is a prescribed medicine used along with diet and exercise to treat adults with nonalcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver. An ongoing Phase III outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (consistent with stage F4c).
Employees
915
Date Price Change Volume
29/07/26 USD 546.88 +1.50% 356,750
28/07/26 USD 538.80 -2.26% 218,771
27/07/26 USD 551.25 +1.24% 268,615
24/07/26 USD 544.51 +0.21% 147,390
23/07/26 USD 543.35 +1.06% 160,514
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
546.88USD
Average target price
680.60USD
Spread / Average Target
+24.45%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MDGL Stock